You are here

Coronary Intervention & Surgery


A cross-sectional study of nearly 1,300 patients revealed Chinese physicians systematically overestimate the severity of coronary stenosis, perhaps even more so than in the United States, likely leading to many patients being inappropriately treated with percutaneous coronary intervention (PCI).

The risk of another heart attack following percutaneous coronary intervention (PCI) was twice as likely to originate from a previously untreated lesion versus the stented lesion, according to a study of a large Swedish cohort published in the Journal of the American Heart Association.

Patients are significantly more likely to die within one year of coronary artery bypass graft (CABG) surgery or PCI in New York state than in England where the procedures are roughly four times cheaper, according to a study in Open Heart.

Temporarily cooling part of the heart during myocardial infarction (MI) and again immediately after angioplasty may reduce damage to the heart, said a cardiologist who participated in the first in-human study of the technique.

Charles E. Chambers, MD, spoke with Cardiovascular Business about the risks of radiation exposure to interventional cardiologists and potential solutions.


Recent Headlines

Abbott restricts use of Absorb BVS in Europe

Abbott Vascular has restricted the use of its Absorb and Absorb GT1 bioresorbable vascular scaffolds (BVS) in Europe to clinical registries.

Researchers pinpoint how cells get damaged during cardiac surgeries

New findings on how cardiac muscle cells are damaged during surgery could point to emerging methods that will allow hearts to recover more quickly.

Transparency helps reduce inappropriate PCI rates

In early 2012, hospitals in New York received reports from the state on their inappropriate PCI rates. The state later published the rates in a medical journal and recommended that payers deny reimbursement for inappropriate PCIs in Medicaid patients.

Researchers will use stem cell therapy to grow heart muscle in new study

The U.S. Food and Drug Administration (FDA) has approved a new study that will test the efficacy of a stem cell technique used on children suffering from congenital heart disease.

PCI operators have significant variability in risk-standardized mortality rates

A registry analysis found there was significant variability in risk-standardized mortality rates among PCI operators who met minimum volume standards. The rates were not consistent on a yearly basis.

Merit Medical recalls device used to guide catheters, grafts into veins, arteries

Merit Medical Systems recalled its Merit 7F Prelude short sheath introducer, which is used to guide the placement of catheters, grafts and other medical devices into the veins and arteries. It is also used during temporary hemodialysis.

ACC.17: LAAO at the time of cardiac surgery may reduce thromboembolism, mortality

Older adults with atrial fibrillation who underwent left atrial appendage occlusion (LAAO) at the time of cardiac surgery had an approximately 40 percent reduction in thromboembolism and a 15 percent reduction in all-cause mortality, according to a database analysis.

ACC.17: Levosimendan improves outcomes for heart surgery patients

Levosimendan, a drug used to prevent heart failure during heart surgery, was shown to not reduce adverse outcomes in patients at a high risk for low cardiac output syndrome in a new study debuted at the American College of Cardiology’s 66th Annual Scientific Session.

ACC.17: ABSORB III trial shows stent associated with increased risk of adverse outcomes

New results on Abbott Vascular’s Absorb everolimus-eluting bioresorbable vascular scaffold (BVS) were revealed at this year’s American College of Cardiology (ACC)’s Scientific Session, providing disappointing results for the stent that are consistent with a trend set by previous studies.

ACC.17: Cerebral embolic protection devices may not improve freedom from stroke, infarction

A randomized study found that using two FDA-approved cerebral embolic protection devices in patients undergoing surgical aortic valve replacement (SAVR) was not associated with an improvement in freedom from clinical or radiographic infarction or clinical stroke.